BioPharmSignal logoBioPharmSignal

Biotech News

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney (PROK)ProKidneyCommercial

Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading

Related news

PROKProKidney2026-06-02 12:00 EST

ProKidney Appoints Kenneth Locke as Chief Technical Officer

PROKProKidney2026-05-15 15:45 EST

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

View all latest news

ProKidney

Regenerative Kidney Medicine ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation. Rilparencel Rilparencel, also known as REACT, is a...

Recent company news

PROKProKidney2026-08-10 20:05 EST

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

PROKProKidney2026-06-02 12:00 EST

ProKidney Appoints Kenneth Locke as Chief Technical Officer

PROKProKidney2026-05-15 15:45 EST

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

PROKProKidney2026-03-25 20:01 EST

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

PROKProKidney2026-03-18 20:00 EST

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

Stock data

Close
1.61 USD
Market cap
389.88M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States